
In this episode of The BioHub by Avetix, I’m joined by Paul Hastings, CEO of Nkarta.Paul has spent more than three decades in biotech, leading companies across oncology, rare disease and cell therapy, while also becoming one of the industry’s most prominent patient advocates. At Nkarta, he’s now leading the development of allogeneic NK cell therapies designed to make cell therapy safer, more scalable and more accessible.We discuss the evolution of biotech since Paul entered the industry in 1989, the future of cell therapy, the challenges of scaling access, the US clinical and regulatory environment, the importance of patient advocacy, and the mentors and lessons that have shaped his career.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Episode 238 - Mandana Honu Fathom Therapeutics

Episode 237 - Marc Hedrick & Russell Bradley- Cerenome

Episode 236 - Dan O’Connell - President & CEO of Acumen Pharmaceuticals

Epsiode 234 - Lei Fang CEO Excalipoint
Free AI-powered recaps of The BioHub - by Avetix and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.